DE60215203D1 - VERWENDUNG VON AMINOMETHYL CHROMANEN ZUR BEHANDLUNG DER NEBENWIRKUNGEN VON NEUROLEPTIkA - Google Patents

VERWENDUNG VON AMINOMETHYL CHROMANEN ZUR BEHANDLUNG DER NEBENWIRKUNGEN VON NEUROLEPTIkA

Info

Publication number
DE60215203D1
DE60215203D1 DE60215203T DE60215203T DE60215203D1 DE 60215203 D1 DE60215203 D1 DE 60215203D1 DE 60215203 T DE60215203 T DE 60215203T DE 60215203 T DE60215203 T DE 60215203T DE 60215203 D1 DE60215203 D1 DE 60215203D1
Authority
DE
Germany
Prior art keywords
neurolepticia
treatment
side effects
chromanes
aminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215203T
Other languages
English (en)
Other versions
DE60215203T2 (de
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Henning Boettcher
Heinz-Hermann Bokel
Uschi Schmid-Grossmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE60215203D1 publication Critical patent/DE60215203D1/de
Application granted granted Critical
Publication of DE60215203T2 publication Critical patent/DE60215203T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60215203T 2001-09-12 2002-08-09 VERWENDUNG VON AMINOMETHYL CHROMANEN ZUR BEHANDLUNG DER NEBENWIRKUNGEN VON NEUROLEPTIkA Expired - Lifetime DE60215203T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01121910 2001-09-12
EP01121910 2001-09-12
PCT/EP2002/008912 WO2003022269A1 (en) 2001-09-12 2002-08-09 Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders

Publications (2)

Publication Number Publication Date
DE60215203D1 true DE60215203D1 (de) 2006-11-16
DE60215203T2 DE60215203T2 (de) 2007-10-18

Family

ID=8178618

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215203T Expired - Lifetime DE60215203T2 (de) 2001-09-12 2002-08-09 VERWENDUNG VON AMINOMETHYL CHROMANEN ZUR BEHANDLUNG DER NEBENWIRKUNGEN VON NEUROLEPTIkA

Country Status (23)

Country Link
US (1) US20040235920A1 (de)
EP (1) EP1425008B1 (de)
JP (1) JP2005522410A (de)
KR (1) KR100886185B1 (de)
CN (1) CN1303996C (de)
AR (1) AR036509A1 (de)
AT (1) ATE341322T1 (de)
AU (1) AU2002331220B2 (de)
BR (1) BR0212199A (de)
CA (1) CA2458628A1 (de)
CY (1) CY1105868T1 (de)
DE (1) DE60215203T2 (de)
DK (1) DK1425008T3 (de)
ES (1) ES2272771T3 (de)
HU (1) HUP0401317A3 (de)
MX (1) MXPA04002304A (de)
MY (1) MY130522A (de)
PL (1) PL207146B1 (de)
PT (1) PT1425008E (de)
RU (1) RU2320336C2 (de)
SI (1) SI1425008T1 (de)
WO (1) WO2003022269A1 (de)
ZA (1) ZA200402774B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012659A2 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CN103402514B (zh) * 2010-10-15 2016-01-13 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE9303274D0 (sv) * 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen

Also Published As

Publication number Publication date
KR20040043175A (ko) 2004-05-22
PL369827A1 (en) 2005-05-02
US20040235920A1 (en) 2004-11-25
PT1425008E (pt) 2007-01-31
JP2005522410A (ja) 2005-07-28
WO2003022269A1 (en) 2003-03-20
RU2004111284A (ru) 2005-05-10
AU2002331220B2 (en) 2007-06-07
AR036509A1 (es) 2004-09-15
PL207146B1 (pl) 2010-11-30
CY1105868T1 (el) 2011-02-02
BR0212199A (pt) 2004-10-05
DK1425008T3 (da) 2007-01-15
MY130522A (en) 2007-06-29
KR100886185B1 (ko) 2009-02-27
CN1555259A (zh) 2004-12-15
RU2320336C2 (ru) 2008-03-27
MXPA04002304A (es) 2004-06-29
CN1303996C (zh) 2007-03-14
ATE341322T1 (de) 2006-10-15
ES2272771T3 (es) 2007-05-01
ZA200402774B (en) 2005-01-13
HUP0401317A2 (en) 2004-10-28
DE60215203T2 (de) 2007-10-18
EP1425008A1 (de) 2004-06-09
EP1425008B1 (de) 2006-10-04
HUP0401317A3 (en) 2007-05-29
CA2458628A1 (en) 2003-03-20
SI1425008T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60211913D1 (de) Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition